Lumiere (bevacizumab biosimilar) / Elea Labs - LARVOL DELTA

[VIRTUAL] Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial” (ASH 2020) - P2 | "The addition of BV to G increases the overall response rate by 15% in the treatment of R/R CD30+ PTCL. OS data are encouraging for this overall R/R patient population but PFS is overall short and a longer FU is mandatory. Especially the DOR of pts achieving CR or PR after 4 cycles of G-BV exceeds 1 year on BV maintenance. This combination is generally well tolerated and this study suggests that G-BV combination could be an interesting alternative for R/R CD30+ PTCL."

Clinical • P2 data • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation • TNFRSF8

Budget Impact of Intravitreal Bevacizumab for the Treatment of Age-Related Macular Degeneration in the Argentinian Health System (ISPOR-EU 2024) - "Ranibizumab (Lucentis), Aflibercept (Eylia) and off-label Bevacizuman are currently the most used antiangiogenics. The Argentinian Regulatory Agency (ANMAT) approved an exclusive intraocular Bevacizumab (Lumiere)... Increase of intravitreal Bevacizumab for managing AMD could contribute to costs saving, ranging from US$49,135,031 to US$297,323,282 over a 5-year period time."

HEOR • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

FETUS: LUMIERE on the PLACENTA (clinicaltrials.gov) - P=N/A; N=0; Withdrawn; Sponsor: Assistance Publique - Hôpitaux de Paris; N=250 ➔ 0; Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • MRI

Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere) in patients with neovascular age-related macular degeneration. (PubMed, Exp Ther Med) - P3 | "no. NCT03668054)."

Clinical • Journal • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

"Et coila les pions vont tomber les uns apres les autres... vive la lumiere de la verité 🙏❤️" (@DhanishtaAquar1)

Nonconventional concept for continuous reproduction of target movement. (PubMed, Appl Opt) - "We demonstrate a novel concept, to the best of our knowledge, for reproduction of the target movement without the frame-by-frame display technique elaborated by the Lumiere brothers...The concept makes it possible to develop new techniques for night vision in the near-infrared and thermal spectra. The path and speed of a bouncing and receding ball in the computer screen animation are recorded and reproduced in 3D."

Journal

"Les lumieres de la ville 😍" (@Milady_Oscar)

LUMIERE on the FETUS (clinicaltrials.gov) - P=N/A; N=650; Recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris; Not yet recruiting ➔ Recruiting; Trial completion date: Sep 2023 ➔ Jun 2023; Trial primary completion date: Mar 2023 ➔ Dec 2022

Enrollment open • Trial completion date • Trial primary completion date

FETUS: LUMIERE on the PLACENTA (clinicaltrials.gov) - P; N=250; Not yet recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris

New trial

LUMIERE on the FETUS (clinicaltrials.gov) - P; N=650; Not yet recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris

New trial

The Haitian Orthopaedic Residency Exchange Program. (PubMed, J Am Acad Orthop Surg Glob Res Rev) - "Twenty-one orthopaedic attendings, 19 South Carolina orthopaedic residents, 22 Haitian orthopaedic residents, and 22 ancillary staff have rotated through Hospital Lumiere...The SCOA Foundation has developed a coordinated service for the musculoskeletal needs of the Haitian people while collaboratively elevating the standard of orthopaedic training in Haiti. We report a collaborative model that other US residency programs can use to impart beneficial changes not only in their home program, but also in training programs abroad."

Journal

"Welcome remarks at #EANO2019 by Pr Jerome Honnorat at a very impressive venue - Grand Lyon Film Festival Lumiere 2019 will be celebrated here in 1 month" (@DrMartaPPrado)